Tuesday May 19 2020 09:27
2 min
Moderna shares jumped another 20% and the S&P 500 rallied over 3% after the US drug maker reported positive results from its early stage trials of its potential Covid-19 vaccine. The news sent risk assets higher as a vaccine would help economies get back to a true normal far quicker than any other measure. But has Moderna really got the goods?
What we know so far:
“These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 [micrograms],” Moderna chief medical officer Dr Tal Zaks said in a statement.
“When combined with the success in preventing viral replication in the lungs of a pre-clinical challenge model at a dose that elicited similar levels of neutralizing antibodies, these data substantiate our belief that mRNA-1273 has the potential to prevent COVID-19 disease and advance our ability to select a dose for pivotal trials,” he added.
Moderna is just one of many drug companies racing to be the first to develop a vaccine against Covid-19.
Shares in Moderna have soared this year by at least 300% to $80 by Monday’s close. It has just announced a new placing to raise $1.3bn at $76, yet shares keep rising and Wall Street still has a strong buy rating on the stock.
Needham recently upgraded its price target on the stock to $94 from $58.
“Based on these data, we believe the vaccine is likely to be found effective for prevention of infection in a Phase 3 trial,” said Needham analyst Alan Carr. “We expect Moderna to have meaningful supply by 4Q20. We have therefore added an mRNA-1273 revenue stream to our model and are raising our price target to $94.”
Risk Warning: this article represents only the author’s views and is for reference only. It does not constitute investment advice or financial guidance, nor does it represent the stance of the Markets.com platform.When considering shares, indices, forex (foreign exchange) and commodities for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss.Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice. Trading cryptocurrency CFDs and spread bets is restricted for all UK retail clients.
Latest
View all
Sunday, 17 August 2025
5 min
Sunday, 17 August 2025
5 min
Sunday, 17 August 2025
5 min
EN
